WO2007073704A1 - Uso tópico del factor de crecimiento epidermico en liposomas para prevenir la amputacion del pie diabético - Google Patents
Uso tópico del factor de crecimiento epidermico en liposomas para prevenir la amputacion del pie diabético Download PDFInfo
- Publication number
- WO2007073704A1 WO2007073704A1 PCT/CU2006/000018 CU2006000018W WO2007073704A1 WO 2007073704 A1 WO2007073704 A1 WO 2007073704A1 CU 2006000018 W CU2006000018 W CU 2006000018W WO 2007073704 A1 WO2007073704 A1 WO 2007073704A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- fce
- growth factor
- liposomes
- epidermal growth
- lesions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1808—Epidermal growth factor [EGF] urogastrone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Definitions
- the present invention relates to topical formulations containing Epidermal Growth Factor encapsulated or associated with deformable or conventional liposomes to be applied on the surface and around chronic ischemic skin lesions, to prevent amputation of the diabetic foot.
- Diabetes Mellitus and its complications are the main non-traumatic cause of amputations of the lower limbs.
- This is a medical problem of increasing importance, since the incidence and prevalence of diabetes must grow in light of the aging populations and the increasingly sedentary lifestyle. In the course of their lives at least 15% of diabetics develop chronic foot ulcers, and of these it is estimated that 20% require limb amputation (Reiber GE, Boyko EJ, Smith DG (1995) Lower extremity foot ulcers and amputations in diabetes In: Harris MI, Cowie CC, Reiber G., Boyko E., Stern M., Bennett P., editors Diabetis in America, Washington, DC: US Government Pr ⁇ nting Office, 409-28; Moss SE, Klein R, Klein BE (1992) The prevalence and incidence of lower extremity amputation in a diabetic population. Arch lnt Med. 152: 610-6).
- Adjuvant measures have also been used, such as hemorrhage therapy and vasoactive therapy, which have provided some favorable effect both in the chronicity phase and in exacerbations but that have not been generalized for the treatment of diabetic foot.
- Hemorrhagic therapy is based on the prevalence shown in the diabetic patient of hemorrhageal alterations and their role in enhancing the infection.
- vasoactive therapy has been used in local perfusion alterations, both due to macro- and micro-angiopathy, in which certain prostanoids act at the tissue level.
- Another invention for the treatment of extensive acute skin lesions, such as venous ulcers, has been the creation of equivalent substitutes for human bioartificial skin.
- the information on ischemic ulcers of the diabetic foot is limited, and it is hardly conceivable that these products can control the underlying ischemic process as a cause of the failure of scarring (New Skin for O ⁇ d. Developments in Biological Skin Substitutes. Arch Dermatol. 1998 134: 344-348).
- Another alternative has been the application of growth factors.
- FDA Federal Food and Drug Administration
- FDA Federal Food and Drug Administration
- PDGF platelet-derived growth factor
- Liposomes have been proposed for use in a wide variety of topical applications since they facilitate the absorption of drugs through the skin, reduce the toxic effects associated with drugs and provide a longer release of these.
- conventional liposomes that are composed of phospholipids and sterols can modulate the penetration of drugs since these vesicles, Although they generally do not penetrate the viable skin, they can accumulate in the stratum corneum and other more superficial layers of the skin (Barry BW (2001) Novel mechanisms and devices to enable successful transdermal drug delivery. Eur J Pharm Sci.
- the present invention solves the aforementioned problem, through the use of topical formulations containing Epidermal Growth Factor encapsulated or associated with deformable or conventional liposomes, which allow a high bioavailability of the FCE in the deep tissue beneath skin lesions, similar to Ia obtained by infiltration of the FCE with hypodermic needles.
- topical formulations containing Epidermal Growth Factor encapsulated or associated with deformable or conventional liposomes, which allow a high bioavailability of the FCE in the deep tissue beneath skin lesions, similar to Ia obtained by infiltration of the FCE with hypodermic needles.
- the application of these topical formulations is carried out on the surface and around chronic ischemic skin lesions and has the advantage that it avoids the pain of the puncture and
- Another aspect of the present invention relates to the topical pharmaceutical formulation, which contains an effective amount of Epidermal Growth Factor encapsulated or associated with deformable or conventional liposomes, in which the liposome is composed of one or more pharmaceutically acceptable lipids.
- the FCE applied through the formulations of this invention is efficiently transported to the viable tissue under the lesions and is effectively protected against protease-mediated degradation, which are present at high levels in these diabetic foot injuries.
- the effective amount of Epidermal Growth Factor is between 0.025 and 0.075 mg / gram of substance.
- the formulations irreversibly allow the healing of chronic skin lesions, preventing the practice of amputations when there is no other alternative for the ischemic limb.
- the liposome of the topical pharmaceutical formulation is composed of one or more pharmaceutically acceptable lipids selected from the group consisting of a neutral lipid, a negative charge lipid, a positive charge lipid, a polyethylene glycol conjugate lipid or a lipid conjugated to a carbohydrate.
- Liposomes may also be composed of one or more pharmaceutically acceptable lipids and one or more non-ionic, zwitterionic, anionic or cationic surfactants.
- Example 1 Obtaining of conventional liposomes loaded with FCE.
- Phosphatidylcholine at a concentration of 10 mg / mL, was dissolved in absolute ethanol in a 50 mL round bottom balloon.
- the lipid was dried by rotary evaporation at room temperature until a dry layer formed on the walls of the container.
- To encapsulate the FCE in liposomes the dried lipid layer was hydrated by homogenization with a buffered solution containing FCE.
- the preparation of liposomes loaded with FCE was subjected to several extrusion passes through a polyethylene carbonate membrane with pores of 100 nm in average diameter until the average size of the liposomes was around 100 nm .
- the suspension was centrifuged at 100,000 xg for 40 min at 4 0 C. The supernatant was transferred to a clean tube and the precipitate was resuspended with a phosphate buffered saline solution. pH 7.2. The centrifugation was repeated once more under the same conditions and the supernatant was transferred to a clean tube and mixed with the supernatant of the first centrifugation. The precipitate (liposomes loaded with FCE) was resuspended in a phosphate buffered saline solution at pH 7.2. This final preparation was stored at 4 0 C until use.
- a total of 85.8 mg of phosphatidylcholine and 11.7 mg of sodium deoxycholate were dissolved in 100 ⁇ l_ of lukewarm absolute ethanol, then they were diluted in 900 ⁇ l_ of phosphate buffer, and swirled until a homogeneous suspension of milky appearance
- This liposome preparation was subjected to several extrusion passes through a polycarbonate membrane with pores of an average diameter of 100 nm until the average size of the liposomes was around 100 nm.
- Example 2 Determination of the efficiency of incorporation of the FCE into the liposomes.
- the preparations were centrifuged at high speed and the protein content in the precipitate (liposomes with incorporated FCE) and in the supernatant (free FCE) obtained was determined.
- the liposome suspension was centrifuged at 100,000 xg for 40 min. at 4 0 C.
- the supernatant was transferred to a clean tube and the precipitate was resuspended with a phosphate buffered saline solution at pH 7.2.
- the centrifugation was repeated under the same conditions and the supernatant was transferred to a clean tube and mixed with the supernatant of the first centrifugation.
- the precipitate was resuspended in 500 ⁇ L of a phosphate buffered saline solution at pH 7.2. Then, the protein present in the supernatant or the precipitate was extracted by adding 0.5% Triton X-100 to the samples and the protein content was quantified by correlation with the area under the curve of the absorbance at 226 nm by means of the reverse phase chromatography of high efficiency (RP-HPLC). Incorporation efficiency was calculated as the protein content ratio in the precipitate (liposomes with FCE incorporated) between the total protein content added at the start of the encapsulation process x 100%.
- Example 3 Determination of the size and morphology of the liposomes.
- Liposome samples were analyzed by transmission electron microscopy to determine the average size of the liposomes and their morphology.
- the liposomes were visualized through negative staining with uranyl acetate.
- the negatively stained samples were observed in a Jeol-JEM 2000EX transmission electron microscope that operated at 80 KV.
- the micrographs of each liposome preparation were digitized using an image digitizer and the diameter of the liposomes contained in each micrograph was measured using the DIGIPAT version 3.3 program (EICISOFT, Havana, Cuba).
- the particle size was averaged by the total number of liposomes present and was represented as the mean + the standard deviation of three independent determinations.
- Both deformable and conventional liposomes loaded with FCE were constituted by a homogeneous population of spherical or ellipsoidal vesicles.
- the average vesicle size was 130 ⁇ 7 nm and 123 ⁇ 4 nm, for conventional liposomes and deformable liposomes, respectively.
- Example 4 Preparation of the gel of liposomes loaded with FCE.
- the deformable or conventional liposomes loaded with FCE were diluted 1.5 times in phosphate buffer pH 7.2 and Carbomer (Carbopol 940) buffered to pH 7.2 was added at a final concentration of 1.25% (w / v).
- the formulation also contained 0.02% (w / v) butyl hydroxytoluene (BHT), 0.1% (w / v) EDTA, 0.25% (w / v) methyl parahydroxybenzoate, 0.525% (w / v) benzyl alcohol, 0.2% ( w / v) sodium hydroxide and 3% (w / v) glycerol.
- the suspensions had a viscosity of approximately 840 mPas and 730 mPas, for conventional liposomes and deformable liposomes, respectively.
- Example 5 Demonstration of the protective effect of the encapsulation of the FCE in liposomes against the enzymatic degradation of the FCE in vitro.
- This experiment had the objective of evaluating whether the encapsulation of the FCE in liposomes (conventional and deformable) is advantageous to preserve the integrity of the FCE in the proteolytic environment of the diabetic foot tissue.
- biopsies of the ulcerated tissue of diabetic patients were taken after local anesthesia and they were resuspended with a phosphate buffered saline solution (PBS pH 7.2). A total of 25 ⁇ g of FCE in solution or encapsulated in liposomes was added to the samples and incubated for 20, 40, or 60 min at 37 ° C.
- PBS pH 7.2 phosphate buffered saline solution
- Example 6 Efficacy demonstrations of topical formulations containing FCE in experimental animal models of acute and controlled torpid lesions.
- mice male Wistar rats of body weight between 225-250 grams. The animals were kept in controlled areas of the BIGerio del CIGB and under a stable lighting regime of 12 x 12 hours, cycles of air changes, as well as free access to the diet. Individual rats were housed in T3 boxes with bed replacement every 48 hours after sterilization. Induction of the ulcers: the animals were anesthetized with the combination of ketamine / xylazine intraperitoneally. The mechanical and chemical depilation of the area of the back from the retro-scapular space to the height of the sacrum was performed. The region was aseptized with a solution of iodine-povidone and isopropyl alcohol.
- the territory of the skin to induce the ulcers was delimited with Chinese ink, to be able to induce total thickness, circular lesions with disposable biomes of 9 mm in diameter (AcuDrem, Fl, USA).
- 6 symmetrical and equidistant lesions were created in each animal. After created, they were washed with sterile saline solution and their inner edge was delineated with indelible ink to calculate the area of the wound in zero time
- the lesions of all the animals in each group were sanitized daily with 70% ethanol and sterile saline before applying the treatment if appropriate.
- Group II-placebo (formulation of deformable liposomes that do not contain FCE) applied topically.
- Group III- treatment by infiltration of an FCE solution containing 75 micrograms per microliter. The infiltrations were performed on the edges and bottom of the wound.
- Time 0- represents 100% of the area of open lesion and 0% of contraction
- Time 1- at 72 hours after induced Time 2- to 5th day of induced
- Time 3- to 7th day of induced Time 4- to 9th day of induced.
- This day is taken as the end of the study and for the sacrifice of the animals according to the previous experience of the spontaneous healing kinetics of these lesions.
- the images of the edges of the lesions were digitized.
- the area and percentage of contraction were calculated using the DIGIPAT image analysis program.
- Statistical calculations Each parameter was performed using the SPSS package using the non-parametric Mann Whitney U test, establishing a significance level of p ⁇ 0.05.
- the animals were sacrificed by an overdose of sodium pentobarbital.
- Hematoxylin / eosin, van Giesson and trichrome stains were used.
- the formulations based on liposomes exert the most potent of the contraction effects of the edges of the wounds, which in other words means that it exerts the most favorable effect on the acceleration of the total healing while the contraction represents the convergence. of several consolidated events that approximate the wound to the remodeling phase.
- Table 4 the percentage of territory occupied by mature and organized granulation tissue of the ulcers in each experimental group can be observed. The calculations were performed on the samples collected in Time 4 quantifying the number of positive microscopic fields coinciding with the reactions of van Giesson and Masson's Trichrome in each sample. The assessments were performed by two pathologists independently and blindly. Table 4. Percentage of granulated territory at time 4 in each experimental group.
- treatment with liposome-based formulations exerts the most potent of the effects on the process of establishment and maturation of granulation tissue, which corresponds to what is described for the wound contraction process described above.
- the effect of the treatments was also studied on the process of epithelialization of the lesions.
- the microscopic aspect of the epithelium was assessed considering the total re-epithelialization of the ulcer, the presence of a stratified epithelium, and the existence of a keratin stratum.
- the lesions were subjected to a central longitudinal hemisection and included in the same paraffin block.
- a total of 120 histological sections were studied per group, which essentially represent 60 lesions. The results are expressed in Table 5.
- Table 5 Effect of treatments on the process of epithelialization of wounds.
- groups IV, V, Vl and VII with the liposome formulations show the best indicators of epithelial response, given by total re-epithelialization and the maturity of the epithelium.
- the experiment described below was carried out with the objective of evaluating the healing effect of the new topical pharmaceutical formulations based on deformable or conventional liposomes containing FCE in chronic lesions with a dark prognosis that simulate the lesion of diabetics.
- Experimental biomodel male Wistar rats of body weight between 225-250 grams. The animals were kept in controlled areas of the BIGerio del CIGB and under a stable lighting regime of 12 x 12 hours, cycles of air changes, as well as free access to the diet. Individual rats were housed in T3 boxes with bed replacement every 48 hours after sterilization.
- Induction of the ulcers The animals were anesthetized with the combination of ketamine / xylazine intraperitoneally. The mechanical and chemical depilation of the area of the back from the retro-scapular space to the height of the sacrum was performed. The region was aseptized with a solution of iodine-povidone and isopropyl alcohol. The territory of the skin to induce the ulcers was delimited with Chinese ink, to be able to induce total thickness, circular lesions with disposable biomes of 9 mm in diameter (AcuDrem, Fl, USA). 6 symmetrical and equidistant lesions were created in each animal as it was done for the previous study.
- mice After created, they were washed with sterile saline solution and their inner edge was delineated with indelible ink for the calculation of the area of the wound in zero time. The lesions of all the animals in each group were sanitized daily with 70% ethanol and sterile saline before applying the treatment if appropriate.
- Experimental groups After the ulcers were created, the animals were randomly assigned by means of a cross order of entry / group table to the following experimental groups: Group I- not treated. Group II-placebo (formulation of deformable liposomes that do not contain FCE) applied topically.
- Group III- treatment by infiltration of an FCE solution containing 75 micrograms per milliliters. The infiltrations were performed on the edges and bottom of the wound.
- Group IV- treatment with the formulation of traditional liposomes containing 25 micrograms of FCE per gram of substance.
- Group VI- treatment with the formulation of deformable liposomes containing 25 micrograms of FCE per gram of substance.
- Group VII- treatment with the formulation of deformable liposomes containing 75 micrograms of FCE per gram of substance.
- Ten rats were included for each of the groups, so that 60 wounds were studied per group.
- the treatments were performed daily, after sedation with diazepam intra-peritoneally of the animals.
- Time 0- represents 100% of the area of open lesion and 0% of contraction
- Time 1- at 72 hours of induced
- Time 2- to 5 t0 day of induced
- Time 3- to 7 or day of induced
- Time 4- to 9 no day of induced
- Time 5 to 12 days of induced and Time 6 to 15 days of created. This day is taken as the end of the study and for the sacrifice of the animals according to the previous experience of the spontaneous healing kinetics of these lesions.
- the images of the edges of the lesions were digitized. The area and percentage of contraction were calculated using the DIGIPAT image analysis program.
- the formulations based on liposomes exert the most potent of the contraction effects of the edges of the wounds, which in other words means that it exerts the most favorable effect on the acceleration of the total healing while the contraction represents the convergence. of several consolidated events that approximate the wound to the remodeling phase. Note that these wounds simulate the biochemical micro-environment of the diabetic wound in which the contraction mechanism is partially or totally abolished pathologically.
- the effect of the treatments was also studied on the process of epithelialization of the lesions.
- the microscopic aspect of the epithelium was assessed considering the total re-epithelialization of the ulcer, the presence of a stratified epithelium, and the existence of a keratin stratum.
- the lesions were subjected to a central longitudinal hemisection and included in the same paraffin block.
- a total of 120 histological sections were studied per group, which essentially represent 60 lesions. There was no need to eliminate any of the bacterial contamination lesions.
- the results are expressed in Table 8. As can be seen, groups IV, V, Vl and VII with the liposome formulations show the best indicators of epithelial response, given by the total re-epithelialization and the maturity of the epithelium.
- treatment with liposomes favors (/) the process of contraction of chronic wounds that faithfully simulate the biochemical environment of the diabetic patient ulcers; (/ ' /) the granulation process and its maturation. Notoriously, the treatment allows the establishment of a neo-formed vascular network and (///) moderately stimulates the process of re-epithelialization and differentiation of the epidermis in lesions that are usually resistant to re-epithelialization.
- Example 7 Demonstration of efficacy of topical formulations containing FCE encapsulated in liposomes in patients with advanced diabetic foot ulcers.
- the compassionate administration of conventional or deformable liposome formulations containing 25 or 75 micrograms of FCE per gram of substance in patients with diabetic foot ulcers have shown similar results to those obtained with the injectable formulation but with the advantage of avoiding the inconveniences of the injections.
- the new formulation of deformable liposomes containing 75 micrograms of FCE per gram of substance was applied in a patient with diabetic foot ulcer, evidence of compromised blood flow and risk of major amputation. The product was administered topically after performing complete debridement of the ulcer.
- the lesion was covered between clergy posts with a dressing and sterile bandage A satisfactory evolution was observed, being evident from the first week of treatment the appearance of a useful granulation tissue and contraction of the edges of the ulcer.
- the product was effective to achieve complete epithelialization of the lesion and prevent amputation. No adverse reactions were identified during treatment.
- the product was also administered topically after complete debridement of the ulcer.
- the lesion was covered between the clergys with a sterile dressing and dressing. From the fourth administration of the product (applied 3 times a week), a substantial change in the appearance of the lesion was observed, in which a bleeding, productive granulation tissue began to prevail, which after a few days was covered by epithelium.
- the patient was discharged from hospital and has evolved without relapse.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- Dispersion Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Dermatology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims
Priority Applications (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/159,159 US20090074850A1 (en) | 2005-12-29 | 2006-12-28 | Use of a topical composition containing epidermal growth factor (egf) for diabetic foot amputation prevention |
BRPI0620733-2A BRPI0620733A2 (pt) | 2005-12-29 | 2006-12-28 | uso de uma quantidade efetiva de fator de crescimento epidérmico encapsulado ou associado a lipossomas deformáveis ou convencionais e formulação farmacêutica tópica |
CA2635013A CA2635013C (en) | 2005-12-29 | 2006-12-28 | Use of a topical composition containing epidermal growth factor (egf) for diabetic foot amputation prevention |
MYPI20082429A MY184122A (en) | 2005-12-29 | 2006-12-28 | Use of topical composition containing epidermal growth factor (egf) for diabetic foot amputation prevention |
DK06828470.2T DK1970071T3 (en) | 2005-12-29 | 2006-12-28 | USE OF A TOPICAL COMPOSITION CONTAINING epidermal growth factor (Epidermal Growth Factor - EGF) FOR PREVENTION OF DIABETIC FODAMPUTATION |
PL06828470T PL1970071T3 (pl) | 2005-12-29 | 2006-12-28 | Wykorzystanie stosowanej zewnętrznie kompozycji zawierającej nabłonkowy czynnik wzrostu (EGF) w celu zapobiegania amputacji stopy cukrzycowej |
AU2006331223A AU2006331223B2 (en) | 2005-12-29 | 2006-12-28 | Use of a topical composition containing epidermal growth factor (EGF) for diabetic foot amputation prevention |
ES06828470.2T ES2527747T3 (es) | 2005-12-29 | 2006-12-28 | Uso tópico de una composición que contiene el factor de crecimiento epidérmico para prevenir la amputación del pie diabético |
SI200631877T SI1970071T1 (sl) | 2005-12-29 | 2006-12-28 | Uporaba topikalne sestave vsebujoäśe epidermalni rastni faktor (egf) za prepreäśevanje diabetiäśne amputacije noge |
JP2008547843A JP5715326B2 (ja) | 2005-12-29 | 2006-12-28 | 糖尿病による足切断を予防するための、上皮成長因子(egf)を含有する局所組成物の使用 |
EP06828470.2A EP1970071B1 (en) | 2005-12-29 | 2006-12-28 | Use of a topical composition containing epidermal growth factor (egf) for diabetic foot amputation prevention |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CU20050282A CU23411B6 (es) | 2005-12-29 | 2005-12-29 | Uso tópico del factor de crecimiento epidérmico en liposomas para prevenir la amputación del pie diabético |
CU2005-0282 | 2005-12-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2007073704A1 true WO2007073704A1 (es) | 2007-07-05 |
Family
ID=37831654
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CU2006/000018 WO2007073704A1 (es) | 2005-12-29 | 2006-12-28 | Uso tópico del factor de crecimiento epidermico en liposomas para prevenir la amputacion del pie diabético |
Country Status (15)
Country | Link |
---|---|
US (1) | US20090074850A1 (es) |
EP (1) | EP1970071B1 (es) |
JP (2) | JP5715326B2 (es) |
KR (1) | KR20080083033A (es) |
CN (2) | CN101374541A (es) |
AR (1) | AR058590A1 (es) |
AU (1) | AU2006331223B2 (es) |
BR (1) | BRPI0620733A2 (es) |
CA (1) | CA2635013C (es) |
CU (1) | CU23411B6 (es) |
MY (1) | MY184122A (es) |
PL (1) | PL1970071T3 (es) |
RU (1) | RU2394590C2 (es) |
WO (1) | WO2007073704A1 (es) |
ZA (1) | ZA200806112B (es) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014019555A1 (es) | 2012-08-02 | 2014-02-06 | Centro De Ingenieria Genetica Y Biotecnologia | Vesiculas que comprenden factor de crecimiento epidermico y composiciones que las contienen |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CU23388B6 (es) * | 2006-01-31 | 2009-07-16 | Ct Ingenieria Genetica Biotech | Composición farmacéutica de microesferas para prevenir la amputación del pie diabético |
US20110308985A1 (en) * | 2009-02-26 | 2011-12-22 | Gina Van Bogaert | Composition of a liposomal gel containing hydrocortisone, its metabolites, precursors or mixtures thereof and the use thereof |
CN102247300A (zh) * | 2010-12-24 | 2011-11-23 | 天津天狮生物发展有限公司 | 人表皮生长因子纳米脂质体及其制备方法 |
CN102302416B (zh) * | 2011-08-26 | 2012-12-05 | 广东丸美生物技术股份有限公司 | 一种辅酶q-10/egf脂质体、制备方法和应用 |
CN102949345A (zh) * | 2012-06-15 | 2013-03-06 | 深圳职业技术学院 | 重组人表皮生长因子阳离子脂质体及其制备方法 |
US11628227B2 (en) * | 2017-07-05 | 2023-04-18 | Wisconsin Alumni Research Foundation | Mineral coated microparticles for gene delivery in chronic wound therapy |
KR101973960B1 (ko) | 2017-09-29 | 2019-04-30 | 티앤에이치바이오(주) | 글루타티온이 함유된 캡슐형 표피 성장 인자의 조성물 및 이로 제조되는 글루타티온이 함유된 캡슐형 표피 성장 인자 |
KR101964156B1 (ko) | 2017-12-27 | 2019-08-07 | 티앤에이치바이오(주) | 표피 성장 인자(egf) 기능 활성화 및 구조 안정화 조성물 |
CN111195230B (zh) * | 2018-11-19 | 2024-01-12 | 奥维嘉生物科技(北京)有限公司 | 一种制备柔性脂质体的方法 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4944948A (en) | 1989-02-24 | 1990-07-31 | Liposome Technology, Inc. | EGF/Liposome gel composition and method |
WO1990011781A1 (en) * | 1989-04-04 | 1990-10-18 | Alcon Laboratories, Inc. | The use of liposomes for the delivery of therapeutic agents to wounds, cuts and abrasions |
WO1991001719A1 (en) * | 1989-08-01 | 1991-02-21 | The University Of Michigan | Topical delivery of peptides/proteins entrapped in dehydration/rehydration liposomes |
WO2003053458A1 (es) | 2001-12-20 | 2003-07-03 | Centro De Ingenieria Genetica Y Biotecnologia | Uso de una composición farmacéutica que contiene factor de crecimiento epidérmico (egf) para la prevención de la amputación del pie diabético |
WO2003075949A1 (en) * | 2002-03-12 | 2003-09-18 | Bio-Click Technologies Ltd. | Method and composition for treating skin wounds with epidermal growth factor |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3990445A (en) * | 1975-01-03 | 1976-11-09 | Valleylab, Inc. | Drug injection device |
DE3837450A1 (de) * | 1988-11-04 | 1990-05-10 | Huels Chemische Werke Ag | Verfahren zur herstellung von 1.1-diphenylethan mit guter geruchsqualitaet |
US5130298A (en) * | 1989-05-16 | 1992-07-14 | Ethicon, Inc. | Stabilized compositions containing epidermal growth factor |
US6165500A (en) * | 1990-08-24 | 2000-12-26 | Idea Ag | Preparation for the application of agents in mini-droplets |
US6635674B1 (en) * | 1998-11-06 | 2003-10-21 | Bristol-Myers Squibb Co. | Pharmaceutical preparations for external use containing non-steroidal anti-inflammatory and analgesic agents |
AU2003225710A1 (en) * | 2002-03-06 | 2003-09-22 | Arizona Board Of Regents | Composition and method for enhancing immune response |
GB0422439D0 (en) * | 2004-10-08 | 2004-11-10 | European Molecular Biology Lab Embl | Inhibitors of infection |
CU23388B6 (es) * | 2006-01-31 | 2009-07-16 | Ct Ingenieria Genetica Biotech | Composición farmacéutica de microesferas para prevenir la amputación del pie diabético |
-
2005
- 2005-12-29 CU CU20050282A patent/CU23411B6/es unknown
-
2006
- 2006-12-20 AR ARP060105657A patent/AR058590A1/es unknown
- 2006-12-28 JP JP2008547843A patent/JP5715326B2/ja not_active Expired - Fee Related
- 2006-12-28 PL PL06828470T patent/PL1970071T3/pl unknown
- 2006-12-28 KR KR1020087018604A patent/KR20080083033A/ko not_active Application Discontinuation
- 2006-12-28 US US12/159,159 patent/US20090074850A1/en not_active Abandoned
- 2006-12-28 CA CA2635013A patent/CA2635013C/en not_active Expired - Fee Related
- 2006-12-28 RU RU2008131070/15A patent/RU2394590C2/ru not_active IP Right Cessation
- 2006-12-28 BR BRPI0620733-2A patent/BRPI0620733A2/pt not_active Application Discontinuation
- 2006-12-28 AU AU2006331223A patent/AU2006331223B2/en not_active Ceased
- 2006-12-28 CN CNA2006800529574A patent/CN101374541A/zh active Pending
- 2006-12-28 WO PCT/CU2006/000018 patent/WO2007073704A1/es active Application Filing
- 2006-12-28 MY MYPI20082429A patent/MY184122A/en unknown
- 2006-12-28 CN CN201510005113.5A patent/CN104623632A/zh active Pending
- 2006-12-28 EP EP06828470.2A patent/EP1970071B1/en not_active Not-in-force
-
2008
- 2008-07-14 ZA ZA200806112A patent/ZA200806112B/xx unknown
-
2013
- 2013-03-13 JP JP2013050061A patent/JP2013107912A/ja active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4944948A (en) | 1989-02-24 | 1990-07-31 | Liposome Technology, Inc. | EGF/Liposome gel composition and method |
WO1990011781A1 (en) * | 1989-04-04 | 1990-10-18 | Alcon Laboratories, Inc. | The use of liposomes for the delivery of therapeutic agents to wounds, cuts and abrasions |
WO1991001719A1 (en) * | 1989-08-01 | 1991-02-21 | The University Of Michigan | Topical delivery of peptides/proteins entrapped in dehydration/rehydration liposomes |
WO2003053458A1 (es) | 2001-12-20 | 2003-07-03 | Centro De Ingenieria Genetica Y Biotecnologia | Uso de una composición farmacéutica que contiene factor de crecimiento epidérmico (egf) para la prevención de la amputación del pie diabético |
US20050107294A1 (en) * | 2001-12-20 | 2005-05-19 | Acosta Jorge B. | Use of pharmaceutical composition containing epidermal growth factor (EGF) for diabetic foot amputation prevention |
WO2003075949A1 (en) * | 2002-03-12 | 2003-09-18 | Bio-Click Technologies Ltd. | Method and composition for treating skin wounds with epidermal growth factor |
Non-Patent Citations (13)
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014019555A1 (es) | 2012-08-02 | 2014-02-06 | Centro De Ingenieria Genetica Y Biotecnologia | Vesiculas que comprenden factor de crecimiento epidermico y composiciones que las contienen |
US9717776B2 (en) | 2012-08-02 | 2017-08-01 | Centro De Ingeniería Genética Y Biotecnología | Vesicles comprising epidermal growth factor and compositions thereof |
US11510965B2 (en) | 2012-08-02 | 2022-11-29 | Centro De Ingeniería Genética Y Biotecnología | Vesicles comprising epidermal growth factor and compositions thereof |
Also Published As
Publication number | Publication date |
---|---|
JP2013107912A (ja) | 2013-06-06 |
RU2394590C2 (ru) | 2010-07-20 |
JP5715326B2 (ja) | 2015-05-07 |
AU2006331223A1 (en) | 2007-07-05 |
CN104623632A (zh) | 2015-05-20 |
MY184122A (en) | 2021-03-19 |
US20090074850A1 (en) | 2009-03-19 |
CN101374541A (zh) | 2009-02-25 |
CA2635013A1 (en) | 2007-07-05 |
AR058590A1 (es) | 2008-02-13 |
BRPI0620733A2 (pt) | 2011-11-22 |
ZA200806112B (en) | 2009-10-28 |
PL1970071T3 (pl) | 2015-05-29 |
EP1970071A1 (en) | 2008-09-17 |
EP1970071B1 (en) | 2014-12-17 |
RU2008131070A (ru) | 2010-02-10 |
KR20080083033A (ko) | 2008-09-12 |
AU2006331223B2 (en) | 2011-12-22 |
JP2009522213A (ja) | 2009-06-11 |
CA2635013C (en) | 2015-09-29 |
AU2006331223A8 (en) | 2008-09-11 |
CU23411B6 (es) | 2009-09-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2007073704A1 (es) | Uso tópico del factor de crecimiento epidermico en liposomas para prevenir la amputacion del pie diabético | |
Alberti et al. | Nanotechnology: A promising tool towards wound healing | |
DK2222327T3 (en) | TOPICAL USE AND FORMULATION OF ERYTHROPOIETIN FOR HEALTH CARE | |
CN104519893B (zh) | 用于治疗细菌感染的包含抗细菌噬菌体的混合物的组合物及其使用方法 | |
JP5219841B2 (ja) | 糖尿病の足切断を防止するためのマイクロスフェア医薬組成物 | |
CA2835492A1 (en) | Novel pharmaceutical formulation | |
AU2013299036C1 (en) | Vesicles which include epidermal growth factor and compositions that contain same | |
JP2007526273A (ja) | キセロゲルまたはフィルムの形態での局所使用のための医薬組成物および製造方法 | |
RU2006104617A (ru) | Способы и фармакологические композиции для заживления ран | |
US20160081968A1 (en) | Composition for use in reducing scab formation and promoting healing | |
PT87886B (pt) | Metodo para a prevencao de deposicao de fibrina ou de formacao de adesoes e processo para a preparacao de composicoes terapeuticas para esse fim | |
ES2527747T3 (es) | Uso tópico de una composición que contiene el factor de crecimiento epidérmico para prevenir la amputación del pie diabético | |
US20200297649A1 (en) | Devices and methods for delivery of oxygen to a wound | |
ITMI20060556A1 (it) | Medicazioni interattive per la cura di patologie dermatologiche | |
MX2008008581A (es) | Uso topico del factor de crecimiento epidermico en liposomas para prevenir la amputacion del pie diabetico | |
US11938173B2 (en) | Use of Clostridium histolyticum protease mixture in promoting wound healing | |
Albertia et al. | Nanotechnology: a promising tool towards wound healing | |
Zeng et al. | Spatiotemporally responsive cascade bilayer microneedles integrating local glucose depletion and sustained nitric oxide release for accelerated diabetic wound healing | |
ES2568517B1 (es) | Composición para liberación controlada de compuestos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
DPE2 | Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2635013 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/a/2008/008581 Country of ref document: MX Ref document number: 2008547843 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 6111/DELNP/2008 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006828470 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006331223 Country of ref document: AU Ref document number: 2008131070 Country of ref document: RU Ref document number: 1020087018604 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200680052957.4 Country of ref document: CN |
|
ENP | Entry into the national phase |
Ref document number: 2006331223 Country of ref document: AU Date of ref document: 20061228 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2006331223 Country of ref document: AU |
|
WWP | Wipo information: published in national office |
Ref document number: 2006828470 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12159159 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: PI0620733 Country of ref document: BR Kind code of ref document: A2 Effective date: 20080627 |